City Therapeutics raises $200 million in upsized US IPO for RNAi drugs
City Therapeutics Inc., an early-stage developer of RNAi-based drugs, raised $200 million in its US initial public offering, pricing shares at $18 at the midpoint of its marketed range. The biotech company is backed by Arch Venture Partners and Fidelity Management.
3 sourcesDrug development
00